Labetalol
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Labetalol: From Hypertension to Malignant Hypertensive Renal Disease
One-Sentence Summary
Labetalol is a combined alpha-1/non-selective beta-adrenergic antagonist, established in clinical practice as an antihypertensive agent. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, but this prediction is currently supported by no clinical trials and no directly relevant literature — it rests on the model’s similarity score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in this evidence pack (data gap). Labetalol’s established pharmacological class is a combined alpha-1/non-selective beta-blocker used in hypertension management; the specific approved indication text was not supplied. |
| Predicted New Indication | Malignant Hypertensive Renal Disease |
| TxGNN Prediction Score | 99.08% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a data gap in this evidence pack). Based on the pharmacological class information accompanying the prediction, Labetalol is a mixed alpha-1/non-selective beta-adrenergic antagonist, which lowers systemic blood pressure and reduces renal vascular resistance.
Malignant hypertensive renal disease is characterised by acute renal arteriolar necrosis driven by severe, uncontrolled hypertension. There is a plausible pharmacological rationale for a blood-pressure-lowering agent to be relevant to this condition — this is the basis of the TxGNN association. However, this evidence pack does not confirm what Labetalol’s original licensed indication actually is, nor does it provide any direct trial or literature evidence connecting Labetalol specifically to this renal condition. The mechanistic link should therefore be treated as a hypothesis generated by the prediction score, not as evidence of clinical efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Labetalol currently has no marketing authorisations on record in this dataset and is listed as Not Marketed in the UK. No product, dosage form, or approved indication details are available to report.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Warnings, contraindications, and drug interaction data were not available in this evidence pack. This is flagged in the source metadata as a Blocking data gap (item: product labelling warnings/contraindications), meaning no formal safety pre-screen (S1 stage) can be completed until this information is obtained.
Other Predicted Indications (Reviewed, Not Advanced)
Three additional TxGNN-predicted indications were reviewed alongside the top candidate; all scored similarly (~99%) but showed no supporting evidence on closer inspection:
- Malignant renovascular hypertension — two case reports retrieved (PMID 7242419, PMID 15113447), but neither discusses Labetalol’s use or efficacy in this specific condition.
- Pulmonary hypertension with unclear multifactorial mechanism (WHO Group 5) — no literature or trials found; beta-blockade is traditionally used cautiously in this population.
- Pulmonary hypertension owing to lung disease/hypoxia (WHO Group 3) — 20 “hypoxia”-tagged articles retrieved, but all are keyword mismatches (e.g. brain ageing, gastric cancer glycolysis, keloid fibroblasts) with no relevance to Labetalol or pulmonary hypertension treatment.
This pattern suggests the literature retrieval for this candidate is currently unreliable and should not be treated as corroborating evidence.
Conclusion and Next Steps
Decision: Hold
Rationale: All four predicted indications sit at Evidence Level L5 (model prediction only) with no clinical trials and no genuinely relevant literature. A Blocking data gap on product safety information (warnings/contraindications) also prevents a formal safety pre-screen.
To proceed, the following is needed:
- Product labelling warnings and contraindications (Blocking gap, DG001)
- Verified mechanism of action from DrugBank (High-priority gap, DG002)
- Confirmed original licensed indication(s) for Labetalol, currently absent from this dataset
- Targeted literature search specifically for “Labetalol” AND “malignant hypertensive renal disease” (or nephrosclerosis/hypertensive emergency) to replace the current non-specific hypoxia-keyword results
- Any UK/international clinical evidence on Labetalol’s use in hypertensive emergency with renal involvement, which would substantially strengthen the mechanistic case
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.